4 news items
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
ZLAB
22 May 24
, Autoimmune & Infectious Diseases, Zai Lab. "ZL-1102 exemplifies the innovative, patient-focused R&D programs in our internal discovery
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
ZLAB
2 Apr 24
These internally discovered programs underscore the Company's focus on extending oncology R&D innovation to people with cancer worldwide
Stock Disconnect Triggers Investor Exodus From CStone Pharma
ZLAB
14 Mar 24
several products, switching its focus to R&D and widening the approved uses for existing medicines
By Molly Wen
Chinese drug
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
ZLAB
13 Mar 24
.
ZL-1310 is a novel and promising ADC within the Zai Lab global oncology R&D pipeline, targeting the Delta-like
- Prev
- 1
- Next